Listar por Categoría
Mostrando ítems 1-20 de 197
-
The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis
(2020-07)Background: Chinese herbal medicine (CHM) is thought to be a potential intervention in the treatment of coronavirus disease (COVID-19). Purpose: This study aimed to investigate the efficacy and safety of CHM or CHM ... -
Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis
(2020-10-02)Introduction: Tocilizumab (TCZ) is an anti-interleukin-6 antibody that has been used for the treatment of severe coronavirus disease 2019 (COVID-19). However, concrete evidence of its benefit in reducing mortality in severe ... -
Advice on the use of point-of-care immunodiagnostic tests for COVID-19. Scientific Brief, 8 April 2020
(2020-04-08)In response to the growing COVID-19 pandemic and shortages of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and begun selling rapid and easy-to-use devices ... -
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
(2020-02-28)Aims: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human ... -
Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients
(2020-03-27)Background: The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak started at the end of 2019 in Wuhan, China, and spread over 100 countries. SARS-CoV-2 uses the membrane protein Angiotensin I ... -
The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects
(2020-04-23)Although infection by SARS-CoV-2, the causative agent of COVID-19, is spreading rapidly worldwide, no drug has been shown to be sufficiently effective for treating COVID-19. We previously found that nafamostat mesylate, ... -
The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections
(2020-05-06)Severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2) is the causative agent of the coronavirus disease‐2019 (COVID‐19) pandemic. Coronaviruses enter cells via fusion of the viral envelope with the plasma membrane ... -
Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review
(2020-10)Abstract The recently known coronavirus, SARS-CoV-2, has turn into the greatest global health challenge, affecting a large number of societies. The lack of specific treatment and gold-standard diagnostic system has made ... -
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
(2020-03-30)Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coron- avirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controver- sial. In ... -
Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?
(2020-06-26)Data sources: The authors of this rapid review did not disclose which electronic databases were included in their literature search. The inclusion and exclusion criteria for the data sources are not reported in the manuscript. ... -
Assessment of Evidence for COVID-19-Related Treatments: Updated 4/17/2020
(2020-04-17)The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each ... -
Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis
(2020-05-08)Background: Recently, chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) have emerged as potential antiviral and immunomodulatory options for the treatment of 2019 coronavirus disease (COVID-19). To examine the ... -
Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19): A protocol for systematic review and meta-analysis
(2020-09-18)Background: The new coronavirus-related pneumonia is causing a global pandemic without specific antiviral drug. Ribavirin has activity against extensive RNA and DNA viruses. We plan to systematically review the use of ... -
Assessment tool for laboratories implementing COVID-19 virus testing. Interim guidance, 8 April 2020
(2020-04-08)Background: This tool has been designed to assess the capacity of laboratories that have implemented or intend to implement testing for SARS-CoV-2, the virus that causes novel coronavirus disease 2019 (COVID-19). The tool ... -
Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
(2020-04-04)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the ongoing pandemic of 2019 CoV disease (COVID-19), which is already responsible for far more deaths than were reported during the ... -
Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies
(2020-02-29)The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is ... -
Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?
(2020-03-26)Because the development of efficacious vaccines and antiviral drugstakes time, vitamin C and other antioxidants are among currently available agentsto mitigate COVID-19 associated ARDS. Given the fact that high-dose VC ... -
Can Nebulised Heparin Reduce Time to Extubation in SARS CoV 2 The CHARTER Study Protocol
(2020-05-12)Introduction: COVID 19 is associated with the development of ARDS displaying the typical features of diffuse alveolar damage with extensive pulmonary coagulation activation resulting in fibrin deposition in the microvasculature ... -
Cell-based therapies for COVID-19: A living, systematic review
(2020-12-17)Objective: This living, systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of cell-based therapies in the treatment of patients with COVID-19. Data ... -
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
(2020-03-27)Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002–2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of ...